v3.25.2
Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disaggregation of Revenue [Line Items]        
Revenues $ 3,675.6 $ 3,547.1 $ 6,704.3 $ 6,692.1
Bayer | Rest Of World | Collaboration revenue | Regeneron's share of profits        
Disaggregation of Revenue [Line Items]        
Revenues 383.4 353.0 700.7 686.9
Bayer | Rest Of World | Collaboration revenue | Reimbursement for manufacturing of commercial supplies        
Disaggregation of Revenue [Line Items]        
Revenues 31.6 22.1 58.2 44.2
Bayer | Rest Of World | R&D expense | Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses        
Disaggregation of Revenue [Line Items]        
Revenues $ (5.6) $ (14.7) $ (15.0) $ (23.4)